top of page
News, Events and Updates
Search
Nov 14, 2011
Anavex Successfully Completes a Phase 1 Clinical Trial for ANAVEX 2-73
Oct 11, 2011
Anavex Appoints Dr. George Tidmarsh as Executive Director
Sep 15, 2011
Anavex Announces Director Resignation
Sep 14, 2011
Anavex to Present Data on ANAVEX 2-73, Lead Compound for Alzheimer's Disease
Jul 25, 2011
Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for AD
Jul 24, 2011
Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology
Jul 15, 2011
Preclinical Development of New Tetrahydrofuran Derivatives Targeting the Sigma-1 Chaperone Protein
Jul 15, 2011
The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau...
Jul 14, 2011
Anavex to Present at Alzheimer's Association International Conference on Alzheimer's Disease
Jul 10, 2011
Anavex Raises $1.575 million
Jul 5, 2011
Anavex Rapidly Advances ANAVEX 2-73 for Alzheimer’s Disease, Phase I Clinical Trial Progressing Well
42
43
44
45
46
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
